Transaction in Own Shares

Summary by AI ^BETAClose X

CVS Group plc has purchased 4,432 ordinary shares at an average price of 1,240.57 pence per share as part of its ongoing share buyback program, with the intention to cancel these shares. Following this transaction, the company will have 70,821,122 ordinary shares in issue, and the total number of voting rights will be the same, serving as the denominator for shareholder notification calculations. Since the program's commencement, CVS has repurchased a total of 919,661 ordinary shares at a weighted average price of 1,216.05 pence per share.

Disclaimer*

CVS Group plc

17 December 2025

CVS GROUP plc

("CVS" or the "Company" and, together with its subsidiaries, the "Group")

Transaction in own shares

CVS announces that on 16 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").

Date of purchase:	16/12/2025
Aggregate number of Ordinary Shares purchased:	4,432
Lowest price paid per share (GBp):	1,228.00
Highest price paid per share (GBp):	1,248.00
Volume weighted average price paid per share (GBp):	1,240.57

CVS intends to cancel all of the purchased Ordinary Shares.

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,821,122 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

The total number of voting rights in CVS is therefore 70,821,122 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

Since the commencement of the Share Buyback Programme, the Company has repurchased 919,661 Ordinary Shares in aggregate at a weighted average price of 1,216.05 pence per share.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.

Individual transactions:

Number of Ordinary Shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Transaction reference number	Trading Venue
Number of Ordinary Shares purchased	Transaction price (GBp share)	Time of transaction (UK Time)	Transaction reference number	Trading Venue
237	1228	16/12/2025 08:27:01	1352700633551196	XLON
630	1230	16/12/2025 11:21:09	1352700633561715	XLON
636	1236	16/12/2025 13:53:15	1352700633570871	XLON
474	1242	16/12/2025 14:26:54	1352700633573429	XLON
289	1242	16/12/2025 14:26:54	1352700633573436	XLON
93	1244	16/12/2025 14:59:42	1352700633578048	XLON
11	1244	16/12/2025 15:28:59	1352700633582307	XLON
143	1244	16/12/2025 15:38:33	1352700633583474	XLON
74	1244	16/12/2025 15:38:33	1352700633583476	XLON
13	1242	16/12/2025 15:56:59	1352700633586344	XLON
48	1242	16/12/2025 15:56:59	1352700633586345	XLON
137	1242	16/12/2025 15:56:59	1352700633586346	XLON
137	1242	16/12/2025 15:56:59	1352700633586347	XLON
26	1242	16/12/2025 15:56:59	1352700633586348	XLON
198	1242	16/12/2025 16:08:52	1352700633589090	XLON
35	1248	16/12/2025 16:27:25	1352700633593369	XLON
110	1248	16/12/2025 16:27:25	1352700633593368	XLON
6	1248	16/12/2025 16:27:25	1352700633593370	XLON
260	1248	16/12/2025 16:27:25	1352700633593372	XLON
83	1248	16/12/2025 16:27:25	1352700633593371	XLON
396	1248	16/12/2025 16:27:32	1352700633593429	XLON
198	1248	16/12/2025 16:27:32	1352700633593428	XLON
198	1248	16/12/2025 16:27:32	1352700633593430	XLON

Contacts

CVS Group plc via Camarco

Richard Fairman, CEO

Robin Alfonso, CFO

Paul Higgs, Chief Veterinary Officer

Charlotte Page, Head of Investor Relations

Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900

Christopher Golden / James Steel / Andrew Clark

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing

Camarco (Financial PR) cvsg@camarco.co.uk

Ginny Pulbrook +44 (0)7961 315 138

Letaba Rimell

Tilly Butcher

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END